ALKEM Stock Overview
Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Alkem Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹4,650.85 |
| 52 Week High | ₹5,520.00 |
| 52 Week Low | ₹3,186.30 |
| Beta | 0.34 |
| 1 Month Change | -4.54% |
| 3 Month Change | -6.31% |
| 1 Year Change | 38.59% |
| 3 Year Change | 66.26% |
| 5 Year Change | 173.03% |
| Change since IPO | 236.60% |
Recent News & Updates
Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13
Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects
Jan 17Recent updates
Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects
Jan 17We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease
Dec 27Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 14Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Aug 02Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Jul 07Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
May 22We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt
Mar 27Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Dec 26These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well
Sep 20Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00
Jul 27Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 13Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Jun 11Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
May 23Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Mar 06Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Feb 21Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Feb 08Should You Be Adding Alkem Laboratories (NSE:ALKEM) To Your Watchlist Today?
Jan 09Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Nov 30Here's Why Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt Responsibly
Nov 17I Built A List Of Growing Companies And Alkem Laboratories (NSE:ALKEM) Made The Cut
Sep 07Here's Why Alkem Laboratories Limited's (NSE:ALKEM) CEO May Deserve A Raise
Aug 20Alkem Laboratories (NSE:ALKEM) Is Increasing Its Dividend To ₹5.00
Aug 03Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Jul 19Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Jul 01Do Alkem Laboratories's (NSE:ALKEM) Earnings Warrant Your Attention?
May 25What Kind Of Investors Own Most Of Alkem Laboratories Limited (NSE:ALKEM)?
Mar 17Why Dividend Hunters Love Alkem Laboratories Limited (NSE:ALKEM)
Mar 04Alkem Laboratories Limited (NSE:ALKEM) Insiders Have Been Selling
Feb 19Do Alkem Laboratories's (NSE:ALKEM) Earnings Warrant Your Attention?
Feb 07Alkem Laboratories (NSE:ALKEM) Could Be A Buy For Its Upcoming Dividend
Feb 07Shareholder Returns
| ALKEM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.6% | -2.2% | -2.1% |
| 1Y | 38.6% | 55.3% | 45.3% |
Return vs Industry: ALKEM underperformed the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: ALKEM underperformed the Indian Market which returned 45.3% over the past year.
Price Volatility
| ALKEM volatility | |
|---|---|
| ALKEM Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: ALKEM has not had significant price volatility in the past 3 months.
Volatility Over Time: ALKEM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 16,871 | Vikas Gupta | www.alkemlabs.com |
Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India.
Alkem Laboratories Limited Fundamentals Summary
| ALKEM fundamental statistics | |
|---|---|
| Market cap | ₹566.06b |
| Earnings (TTM) | ₹15.73b |
| Revenue (TTM) | ₹126.34b |
35.3x
P/E Ratio4.4x
P/S RatioIs ALKEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALKEM income statement (TTM) | |
|---|---|
| Revenue | ₹126.34b |
| Cost of Revenue | ₹52.00b |
| Gross Profit | ₹74.35b |
| Other Expenses | ₹58.62b |
| Earnings | ₹15.73b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 131.58 |
| Gross Margin | 58.85% |
| Net Profit Margin | 12.45% |
| Debt/Equity Ratio | 14.1% |
How did ALKEM perform over the long term?
See historical performance and comparison